PRESS RELEASE published on 10/23/2023 at 09:00, 2 years 5 months ago Eckert & Ziegler to Supply Ablaze Pharmaceuticals with Lutetium-177 for Clinical Trials
PRESS RELEASE published on 10/20/2023 at 15:40, 2 years 5 months ago Eckert & Ziegler and Supervisory Board Decide on Investment Priorities for 2024: Focus on Core Competencies and Split-Off of Pentixapharm AG
PRESS RELEASE published on 10/20/2023 at 15:18, 2 years 5 months ago EQS-Adhoc: Eckert & Ziegler Focuses on Core Competence and Prepares Split-Off of Clinical Assets
PRESS RELEASE published on 10/17/2023 at 16:57, 2 years 5 months ago EQS-Adhoc: Eckert & Ziegler Achieves Double-Digit Growth in Q3 versus Previous Year. Significant Jump in Sales also in First 9 Months, Earnings still Burdened by Special Items Compared to Same Period Last Year.
PRESS RELEASE published on 10/10/2023 at 15:00, 2 years 5 months ago Eckert & Ziegler and PharmaLogic Sign Reservation Agreement for Supply of Therapeutic Radioisotope Actinium-225
PRESS RELEASE published on 09/28/2023 at 10:00, 2 years 5 months ago Eckert & Ziegler Receives Award for Professional Training
PRESS RELEASE published on 09/25/2023 at 23:17, 2 years 6 months ago EQS-Adhoc: Eckert & Ziegler Signs Strategically Important Agreement for the Supply of Lutetium-177 with POINT Biopharma
PRESS RELEASE published on 09/13/2023 at 15:00, 2 years 6 months ago Eckert & Ziegler collaborates with RefleXion Medical and Telix Pharmaceuticals to Expand Treatment Options for Prostate Cancer Patients
PRESS RELEASE published on 08/10/2023 at 07:45, 2 years 7 months ago Eckert & Ziegler Continues Positive Sales Development in the First Half of 2023
PRESS RELEASE published on 07/21/2023 at 15:21, 2 years 8 months ago EQS-Adhoc: Eckert & Ziegler again achieves sales growth compared to the previous year and confirms its forecast for 2023. Decline in earnings compared to same period last year due to extraordinary items.
Published on 03/26/2026 at 23:00, 3 hours 29 minutes ago FutureGen Industries Announces Closing of Debt Settlement
Published on 03/26/2026 at 22:05, 4 hours 24 minutes ago BlackBerry to Announce Fourth Quarter and Fiscal Year 2026 Results on April 9, 2026
Published on 03/26/2026 at 22:00, 4 hours 29 minutes ago Clean Air Metals Receives Provincial Funding and Provides Update on the Thunder Bay North Project
Published on 03/26/2026 at 22:00, 4 hours 29 minutes ago Green Bridge Metals Reports Visible Copper Sulfide Mineralization in Initial 2026 Titac Drilling, Duluth Complex Minnesota
Published on 03/26/2026 at 21:00, 5 hours 29 minutes ago Worksport Reports Record FY 2025 Results, Issues $35M–$42M 2026 Revenue Guidance; Targets Initial Cash Flow Positivity
Published on 03/26/2026 at 20:48, 5 hours 41 minutes ago Dermapharm Holding SE repurchases 4,299,190 shares under its public share buyback offer
Published on 03/26/2026 at 19:20, 7 hours 9 minutes ago Critical Path Institute Launches 'One to Millions' to Reshape the Future of Individualized Medicine at Global Scale
Published on 03/26/2026 at 19:09, 7 hours 19 minutes ago 2CRSi SA: First Half 2025/26 Results: Revenue of €204.7 million (x9.8) EBITDA of €9.6 million (x4.6)
Published on 03/26/2026 at 18:17, 8 hours 12 minutes ago Eiffage strengthens its position in Getlink capital
Published on 03/26/2026 at 07:30, 18 hours 59 minutes ago BIOPHYTIS-LYNXKITE ALLIANCE INVITED TO NVIDIA CONFERENCE: UNLEASHING AI TO REVOLUTIONIZE LONGEVITY
